The COVID-19 pandemic reached the state of Nagaland on 22 May 2020, with its first case confirmed on 25 May 2020.[1]
Officially, Nagaland is the last of the northeastern states after Sikkim to report COVID-19 positive cases.
The man had been admitted to a private hospital in Dimapur for treatment but the hospital referred him to the GMCH as the State did not have testing facilities at that point of time. He tested positive hours after he was shifted in an ambulance.
The first special train carrying over 1469 people, who were stranded in Chennai, reached Dimapur at around 6:20 pm on 22 May. The returnees, mostly students and migrant workers, had started their journey from Chennai on 19 May.[2]
On 25 May, the Nagaland state Department of Health and Family Welfare reported the first official cases in the state — three people – two men and a woman – who returned from Chennai on 22 May tested positive for the novel coronavirus.[3]
As of 1 September, the total number of cases in Nagaland was 4003, including 794 active cases and 3191 recoveries. Eight people died from the virus.[4]
On 12 September, Nagaland's total covid cases crossed 5000 mark.[6]
As of 28 September, the total number of cases was 5957, including 1002 active cases, 4897 recoveries and 12 deaths.[4]
On January 1, 2021, the Drug Controller General of India, approved the emergency or conditional use of AstraZeneca's COVID-19 vaccine AZD1222 (marketed as Covishield).[9] Covishield is developed by the University of Oxford and its spin-out company, Vaccitech.[10] It's a viral vector vaccine based on replication-deficient Adenovirus that causes cold in Chimpanzees.
It can be stored, transported and handled at normal refrigerated conditions (two-eight degrees Celsius/ 36-46 degrees Fahrenheit). It has a shelf life of at least six months.